World's Best Scientists 2026 revealed!
Kent J. Weinhold

Kent J. Weinhold

D-Index & Metrics

Immunology

D-Index
78
Citations
23493
World Ranking
1747
National Ranking
860

Medicine

D-Index
78
Citations
23493
World Ranking
18002
National Ranking
8974

Kent J. Weinhold publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Kent J. Weinhold sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 234 publications — 46th percentile

46% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Kent J. Weinhold D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Kent J. Weinhold sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 78 D-Index — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Kent J. Weinhold is affiliated with Duke University in the United States and has a research focus spanning medicine, immunology, and microbiology. Their work includes a significant body of publications related to oncology, immunology, molecular biology, genetics, and surgery. Weinhold's contributions primarily explore cancer immunotherapy and biomarkers, immune cell function and interaction, as well as immunotherapy and immune responses.

Their research encompasses several important topics, notably:

  • Cancer Immunotherapy and Biomarkers
  • Immune Cell Function and Interaction
  • Immunotherapy and Immune Responses
  • CAR-T cell therapy research
  • Lung Cancer Research Studies
  • Chronic Lymphocytic Leukemia Research
  • Glioma Diagnosis and Treatment

Weinhold has published in a range of scientific journals, with frequent appearances in the following venues:

  • Journal of Clinical Oncology
  • UNC Libraries
  • Frontiers in Immunology
  • Clinical Cancer Research
  • Journal for ImmunoTherapy of Cancer

Collaborations are a notable aspect of Weinhold's research, working repeatedly with several co-authors:

  • Janet Staats
  • John H. Sampson
  • Scott Antonia
  • Jennifer Enzor
  • Simon G. Gregory

Among recent papers, Weinhold's publication record includes studies focused on immunotherapy and cancer treatment methodologies:

  • Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial (2024, The Lancet)
  • FlowKit: A Python Toolkit for Integrated Manual and Automated Cytometry Analysis Workflows (2021, Frontiers in Immunology)
  • A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer (2020, Cancer)
  • A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer (2022, Prostate Cancer and Prostatic Diseases)
  • Wnt activation promotes memory T cell polyfunctionality via epigenetic regulator PRMT1 (2022, Journal of Clinical Investigation)

The breadth of Weinhold's work is anchored in therapeutic strategies within oncology and immune system modulation, integrating clinical trials and bioinformatics tools. Their studies often involve novel combinations of immunotherapeutic agents and provide insights into the immune mechanisms relevant to cancer treatment.

Best Publications

  • 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

    H Mitsuya;K J Weinhold;P A Furman;M H St Clair

  • Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.

    P A Furman;J A Fyfe;M H St Clair;K Weinhold

  • ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX

    Robert Yarchoan;Kent J. Weinhold;H. Kim Lyerly;Edward Gelmann

  • Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia

    Georgia D. Tomaras;Nicole L. Yates;Pinghuang Liu;Li Qin

  • Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant.

    G J LaRosa;J P Davide;K Weinhold;J A Waterbury

  • The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection

    Nilu Goonetilleke;Michael K.P. Liu;Jesus F. Salazar-Gonzalez;Guido Ferrari

  • Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides

    Thomas J. Palker;Michael E. Clark;Alphonse J. Langlois;Thomas J. Matthews

  • T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma

    Karolina Woroniecka;Pakawat Chongsathidkiet;Kristen Rhodin;Hanna Kemeny

  • HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope

    SD Putney;TJ Matthews;WG Robey;DL Lynn

  • A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study.

    Hamilton Jd;Hartigan Pm;Simberkoff Ms;Day Pl

  • 3'-azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase

    M H St Clair;C A Richards;T Spector;K J Weinhold

  • Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack

    H K Lyerly;T J Matthews;A J Langlois;D P Bolognesi

  • Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion

    T J Matthews;K J Weinhold;H K Lyerly;A J Langlois

  • Clade B-Based HIV-1 Vaccines Elicit Cross-Clade Cytotoxic T Lymphocyte Reactivities in Uninfected Volunteers

    Guido Ferrari;Will Humphrey;M. Juliana McElrath;Jean–Louis Excler

  • Immune Responses to Human Immunodeficiency Virus (HIV) Type 1 Induced by Canarypox Expressing HIV-1MN gp120, HIV-1SF2 Recombinant gp120, or Both Vaccines in Seronegative Adults

    Mary Lou Clements-Mann;Kent Weinhold;Thomas J. Matthews;Barney S. Graham

  • Standardization of cytokine flow cytometry assays

    Holden T Maecker;Aline Rinfret;Patricia D'Souza;Janice Darden

  • HIV-1 GP120-mediated immune suppression and lymphocyte destruction in the absence of viral infection.

    K J Weinhold;H K Lyerly;S D Stanley;A A Austin

  • High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses.

    Justin Pollara;Lydia Hart;Faraha Brewer;Joy Pickeral

  • A Canarypox Vaccine Expressing Multiple Human Immunodeficiency Virus Type 1 Genes Given Alone or with Rgp120 Elicits Broad and Durable CD8+ Cytotoxic T Lymphocyte Responses in Seronegative Volunteers

    Thomas G. Evans;Michael C. Keefer;Kent J. Weinhold;Mark Wolff

  • Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.

    Robert B. Belshe;Geoffrey J. Gorse;Mark J. Mulligan;Thomas G. Evans

  • Analysis of the adult thymus in reconstitution of T lymphocytes in HIV-1 infection

    Barton F. Haynes;Laura P. Hale;Kent J. Weinhold;Dhavalkumar D. Patel

  • Human Immunodeficiency Virus Type 1 gp41 Antibodies That Mask Membrane Proximal Region Epitopes: Antibody Binding Kinetics, Induction, and Potential for Regulation in Acute Infection

    S. Munir Alam;Richard M. Scearce;Robert J. Parks;Kelly Plonk

  • Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.

    Robert B. Belshe;Cladd Stevens;Geoffrey J. Gorse;Susan Buchbinder

  • Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection

    Michael R. Betts;Barbara Exley;David A. Price;Anju Bansal

  • QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans

    Thomas G. Evans;M.Juliana McElrath;Tom Matthews;David Montefiori

Frequent Co-Authors

Dani P. Bolognesi
Dani P. Bolognesi Duke University
Guido Ferrari
Guido Ferrari Duke University
Barton F. Haynes
Barton F. Haynes Duke University
Georgia D. Tomaras
Georgia D. Tomaras Duke University
Michael C. Keefer
Michael C. Keefer University of Rochester
M. Juliana McElrath
M. Juliana McElrath University of Washington
David C. Montefiori
David C. Montefiori Duke University
John Bartlett
John Bartlett Duke University
Barney S. Graham
Barney S. Graham Morehouse School of Medicine
Thomas J. Matthews
Thomas J. Matthews University of Birmingham

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a degree in Immunology opens doors to various healthcare career paths, many of which are accessible through accelerated and flexible online programs. For those with a non-nursing background interested in healthcare, exploring accelerated bsn programs for non nurses can be an efficient way to transition into nursing while building a strong foundation in patient care.

Licensed practical nursing is another pathway for quickly entering the healthcare field, where graduates can gain hands-on experience. The fastest and easiest lpn programs online are designed to help students complete their studies promptly while meeting necessary licensure requirements.

Advancing beyond nursing roles, students can consider specialized programs, such as the easiest nurse practitioner program, which offers flexible options to help nurses enhance their clinical skills and knowledge. For those drawn to mental health, the top pmhnp programs focus on psychiatric mental health nurse practitioner roles, providing strong clinical placement opportunities to support career success.

By choosing the right online degree program aligned with Immunology, learners can accelerate their careers in healthcare and make a meaningful impact in both research and patient care settings.

Best Scientists Citing Kent J. Weinhold

Trending Scientists

Recently Published Articles